36.30
price up icon0.96%   0.345
after-market アフターアワーズ: 36.31 0.005 +0.01%
loading
前日終値:
$35.96
開ける:
$35.2
24時間の取引高:
1.29M
Relative Volume:
0.47
時価総額:
$6.37B
収益:
$217.77M
当期純損益:
$-438.86M
株価収益率:
-15.06
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
+7.19%
1か月 パフォーマンス:
-1.18%
6か月 パフォーマンス:
+52.29%
1年 パフォーマンス:
+49.22%
1日の値動き範囲:
Value
$35.13
$36.35
1週間の範囲:
Value
$33.21
$36.35
52週間の値動き範囲:
Value
$21.62
$39.47

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
名前
Bridgebio Pharma Inc
Name
セクター
Healthcare (1167)
Name
電話
(650) 391-9740
Name
住所
3160 PORTER DR., PALO ALTO, CA
Name
職員
730
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
BBIO's Discussions on Twitter

BBIO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
36.30 6.37B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-31 開始されました Redburn Atlantic Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-03 開始されました Oppenheimer Perform
2024-09-04 開始されました Piper Sandler Overweight
2024-03-21 再開されました Raymond James Outperform
2024-01-31 開始されました BMO Capital Markets Market Perform
2023-12-08 開始されました Wells Fargo Overweight
2023-11-07 開始されました Citigroup Buy
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-07-18 ダウングレード Jefferies Buy → Hold
2023-04-19 開始されました Evercore ISI Outperform
2023-02-06 開始されました Cowen Outperform
2021-12-27 繰り返されました Mizuho Buy
2021-12-27 繰り返されました SVB Leerink Outperform
2021-09-10 アップグレード BofA Securities Neutral → Buy
2021-05-21 開始されました UBS Buy
2021-03-22 繰り返されました Goldman Buy
2021-02-22 再開されました JP Morgan Overweight
2021-02-09 再開されました Goldman Buy
2021-01-11 繰り返されました H.C. Wainwright Buy
2020-12-10 繰り返されました H.C. Wainwright Buy
2020-06-25 開始されました BofA/Merrill Neutral
2020-05-19 開始されました BTIG Research Buy
2020-04-13 開始されました H.C. Wainwright Buy
2020-02-19 開始されました Mizuho Buy
2019-07-26 開始されました Raymond James Outperform
2019-07-22 開始されました BMO Capital Markets Outperform
2019-07-22 開始されました Goldman Buy
2019-07-22 開始されました JP Morgan Overweight
2019-07-22 開始されました Jefferies Buy
2019-07-22 開始されました Piper Jaffray Overweight
2019-07-22 開始されました SVB Leerink Outperform
すべてを表示

Bridgebio Pharma Inc (BBIO) 最新ニュース

pulisher
Apr 23, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO) - PrimePublishers.com

Apr 23, 2025
pulisher
Apr 22, 2025

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events - ADVFN

Apr 22, 2025
pulisher
Apr 22, 2025

BridgeBio: Early Signs Point To Blockbuster Revenues - Seeking Alpha

Apr 22, 2025
pulisher
Apr 22, 2025

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET | BBIO Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

BridgeBio Pharma, Inc. to Report First Quarter Financial Results and Program Updates on April 29, 2025 - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET - TradingView

Apr 22, 2025
pulisher
Apr 22, 2025

BridgeBio Sets Q1 2025 Earnings Call: Key Genetic Disease Pipeline Updates Expected April 29 - Stock Titan

Apr 22, 2025
pulisher
Apr 16, 2025

BridgeBio Pharma director Ellis sells $350,000 in stock By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

BridgeBio Pharma director Ellis sells $350,000 in stock - Investing.com Australia

Apr 16, 2025
pulisher
Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool

Apr 15, 2025
pulisher
Apr 15, 2025

BridgeBio (BBIO) Receives Increased Price Target from H.C. Wainw - GuruFocus

Apr 15, 2025
pulisher
Apr 12, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

BridgeBio Pharma (BBIO) Sees Promising Growth Amid Market Volati - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

BridgeBio Expands Team: Strategic Equity Grants Awarded to 20 New Hires - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX) - The Globe and Mail

Apr 10, 2025
pulisher
Apr 04, 2025

BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 03, 2025

BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq

Apr 03, 2025
pulisher
Apr 01, 2025

Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire

Apr 01, 2025
pulisher
Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: New ATTR-CM Drug Shows Dramatic 59% Risk Reduction in Phase 3 Trial - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus

Mar 29, 2025
pulisher
Mar 29, 2025

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

(BBIO) Technical Data - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 29, 2025

Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN

Mar 29, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio’s Beyonttra approved in Japan - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan

Mar 27, 2025
pulisher
Mar 24, 2025

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR

Mar 24, 2025
pulisher
Mar 23, 2025

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN

Mar 23, 2025
pulisher
Mar 22, 2025

BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com

Mar 22, 2025
pulisher
Mar 21, 2025

Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com

Mar 21, 2025

Bridgebio Pharma Inc (BBIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
大文字化:     |  ボリューム (24 時間):